Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017

Bassam H Mahboub 1 2, Mayank Gian Vats 2, Ashraf Al Zaabi 3, Mohammed Nizam Iqbal 2, Tarek Safwat 4, Fatma Al-Hurish 5, Marc Miravitlles 6, Dave Singh 7, Khaled Asad 8, Salah Zeineldine 9 10, Mohamed S Al-Hajjaj 1

Affiliations

09 October 2017

-

doi: 10.2147/COPD.S136245

Abstract

Smoking and subsequent development of COPD is an ever-increasing epidemic in Arabian Gulf and Middle East countries, with no signs of decline. The important fact to be highlighted is that this COPD epidemic of increasing incidence and prevalence is mostly unrecognized by patients, due to the common attribution of symptoms to "smoker's cough", and the underdiagnosis and undertreatment by physicians because the common signs and symptoms masquerade as asthma. Consequently, there are long-term adverse effects of missing the diagnosis. The purpose of this review article is to focus upon the status of COPD in Arabian Gulf and Middle East countries, stressing the increasing burden of smoking and COPD, to emphasize the specific factors leading to rise in prevalence of COPD, to bring to light the underdiagnosis and undermanagement of COPD, and to treat COPD in conformity with standard guidelines with local and regional modifications. This review ends with suggestions and recommendations to the health department to formulate policies and to generate awareness among the general public about the side effects of smoking and consequences of COPD.

Keywords: COPD; Gulf Cooperation Council countries; Middle East; bakhour; medwakh; prevalence of smoking; shisha; water pipe.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work

Similar articles

Unmet need in the management of chronic obstructive pulmonary disease in the Middle East and Africa region: An expert panel consensus.

Al-Moamary MS, Köktūrk N, Idrees MM, Şen E, Juvelekian G, Saleh WA, Zoumot Z, Behbehani N, Hatem A, Masoud HH, Snouber A, van Zyl-Smit RN.Respir Med. 2021 Nov-Dec;189:106641. doi: 10.1016/j.rmed.2021.106641. Epub 2021 Oct 5.PMID: 34649155 Review.

Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies.

Rossi A, Butorac-Petanjek B, Chilosi M, Cosío BG, Flezar M, Koulouris N, Marin J, Miculinic N, Polese G, Samaržija M, Skrgat S, Vassilakopoulos T, Vukić-Dugac A, Zakynthinos S, Miravitlles M.Int J Chron Obstruct Pulmon Dis. 2017 Aug 29;12:2593-2610. doi: 10.2147/COPD.S132236. eCollection 2017.PMID: 28919728 Free PMC article. Review.

Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history.

Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, Ohar JA, Kraft M, Mannino DM, Strange C.Int J Chron Obstruct Pulmon Dis. 2015 Jul 21;10:1409-16. doi: 10.2147/COPD.S82259. eCollection 2015.PMID: 26229460 Free PMC article.

Continuing to confront COPD International Surveys: comparison of patient and physician perceptions about COPD risk and management.

Menezes AM, Landis SH, Han MK, Muellerova H, Aisanov Z, van der Molen T, Oh YM, Ichinose M, Mannino DM, Davis KJ.Int J Chron Obstruct Pulmon Dis. 2015 Jan 20;10:159-72. doi: 10.2147/COPD.S74315. eCollection 2015.PMID: 25653515 Free PMC article.

Impact of active and passive smoking as risk factors for asthma and COPD in women presenting to primary care in Syria: first report by the WHO-GARD survey group.

Mohammad Y, Shaaban R, Al-Zahab BA, Khaltaev N, Bousquet J, Dubaybo B.Int J Chron Obstruct Pulmon Dis. 2013;8:473-82. doi: 10.2147/COPD.S50551. Epub 2013 Oct 2.PMID: 24124359 Free PMC article.

Cited by

Update on Asthma-COPD Overlap (ACO): A Narrative Review.

Mekov E, Nuñez A, Sin DD, Ichinose M, Rhee CK, Maselli DJ, Coté A, Suppli Ulrik C, Maltais F, Anzueto A, Miravitlles M.Int J Chron Obstruct Pulmon Dis. 2021 Jun 17;16:1783-1799. doi: 10.2147/COPD.S312560. eCollection 2021.PMID: 34168440 Free PMC article. Review.

Gaps in COPD Guidelines of Low- and Middle-Income Countries: A Systematic Scoping Review.

Tabyshova A, Hurst JR, Soriano JB, Checkley W, Wan-Chun Huang E, Trofor AC, Flores-Flores O, Alupo P, Gianella G, Ferdous T, Meharg D, Alison J, Correia de Sousa J, Postma MJ, Chavannes NH, van Boven JFM.Chest. 2021 Feb;159(2):575-584. doi: 10.1016/j.chest.2020.09.260. Epub 2020 Oct 8.PMID: 33038390 Free PMC article.

Asthma control factors in the Gulf Cooperation Council (GCC) countries and the effectiveness of ICS/LABA fixed dose combinations: a dual rapid literature review.

Noibi S, Mohy A, Gouhar R, Shaker F, Lukic T, Al-Jahdali H.BMC Public Health. 2020 Aug 8;20(1):1211. doi: 10.1186/s12889-020-09259-3.PMID: 32770967 Free PMC article. Review.

The characteristics of the frequent exacerbators with chronic bronchitis phenotype and the asthma-chronic obstructive pulmonary disease overlap syndrome phenotype in chronic obstructive pulmonary disease patients: A meta-analysis and system review.

Wu JJ, Xu HR, Zhang YX, Li YX, Yu HY, Jiang LD, Wang CX, Han M.Medicine (Baltimore). 2019 Nov;98(46):e17996. doi: 10.1097/MD.0000000000017996.PMID: 31725666 Free PMC article.

Aberrant MicroRNAomics in Pulmonary Complications: Implications in Lung Health and Diseases.

Dutta RK, Chinnapaiyan S, Unwalla H.Mol Ther Nucleic Acids. 2019 Dec 6;18:413-431. doi: 10.1016/j.omtn.2019.09.007. Epub 2019 Sep 18.PMID: 31655261 Free PMC article. Review.

References

  1.  
    1. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. 2017. [Accessed January 12, 2017]. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-preve.... - PubMed
  2.  
    1. Murray CJ, Lopez AD, Mathers CD, Stein C. The Global Burden of Disease 2000 project: aims, methods and data sources. 2001. [Accessed January 22, 2017]. Available from: http://www.who.int/healthinfo/paper36.pdf.
  3.  
    1. World Health Organization . The Global Burden of Disease: 2004 Update. Geneva: WHO; 2008.
  4.  
    1. Devine JF. Chronic obstructive pulmonary disease: an overview. Am Health Drug Benefits. 2008;1:34–42. - PMC - PubMed
  5.  
    1. World Health Organization . Risk factors for chronic respiratory diseases. In: Bousquet J, Khaltaev N, editors. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. Geneva: WHO; 2007. pp. 37–55.
  6.  
    1. Khattab A, Javaid A, Iraqi G, et al. Smoking habits in the Middle East and North Africa: results of the BREATHE study. Respir Med. 2012;106(Suppl 2):S16–S24. - PubMed
  7.  
    1. Riachy M, Rehayem C, Khoury C, et al. Are narghile smokers different from cigarette smokers? Rev Mal Respir. 2008;25:313–318. French. - PubMed
  8.  
    1. Neergaard J, Singh P, Job J, Montgomery S. Waterpipe smoking and nicotine exposure: a review of the current evidence. Nicotine Tob Res. 2007;9:987–994. - PMC - PubMed
  9.  
    1. Maziak W, Eissenberg T, Ward KD. Patterns of waterpipe use and dependence: implications for intervention development. Pharmacol Biochem Behav. 2005;80:173–179. - PubMed
  10.  
    1. Lindberg A, Eriksson B, Larsson LG, Rönmark E, Sandström T, Lundbäck B. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest. 2006;129:879–885. - PubMed
  11.  
    1. Kan H, Heiss G, Rose KM, Whitsel E, Lurmann F, London SJ. Traffic exposure and lung function in adults: the Atherosclerosis Risk in Communities study. Thorax. 2007;62:873–879. - PMC - PubMed
  12.  
    1. Polatli M, Kheder AB, Wali S, et al. Chronic obstructive pulmonary disease and associated healthcare resource consumption in the Middle East and North Africa: the BREATHE study. Respir Med. 2012;106(Suppl 2):S75–S85. - PubMed
  13.  
    1. Yin P, Jiang CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort study. Lancet. 2007;370:751–757. - PubMed
  14.  
    1. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH, Blanc PD. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health. 2005;4:7. - PMC - PubMed
  15.  
    1. Hu G, Zhou Y, Tian J, et al. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest. 2010;138:20–31. - PubMed
  16.  
    1. Lin TC, Krishnaswamy G, Chi DS. Incense smoke: clinical, structural and molecular effects on airway disease. Clin Mol Allergy. 2008;6:3. - PMC - PubMed
  17.  
    1. Cohen R, Sexton KG, Yeatts KB. Hazard assessment of United Arab Emirates (UAE) incense smoke. Sci Total Environ. 2013;458–460:176–186. - PubMed
  18.  
    1. El Hasnaoui A, Rashid N, Lahlou A, Salhi H, Doble A, Nejjari C. Chronic obstructive pulmonary disease in the adult population within the Middle East and North Africa region: rationale and design of the BREATHE study. Respir Med. 2012;106(Suppl 2):S3–S15. - PubMed
  19.  
    1. World Health Organization Chronic obstructive pulmonary disease (COPD) 2016. [Accessed January 15,2017]. Available from: www.who.int/mediacentre/factsheets/fs315/en.
  20.  
    1. Adeloye D, Chua S, Lee CW, et al. Global and regional estimates of COPD prevalence: systemic review and meta-analysis. J Glob Health. 2015;5:020415. - PMC - PubMed
  21.  
    1. Tageldin MA, Nafti S, Khan JA, et al. Distribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE study. Respir Med. 2012;106(Suppl 2):S25–S32. - PubMed
  22.  
    1. Al Zaabi A, Asad F, Abdou J, et al. Prevalence of COPD in Abu Dhabi, United Arab Emirates. Respir Med. 2011;105:566–570. - PubMed
  23.  
    1. Mahboub B, Alzaabi A, Soriano JB, et al. Case-finding of chronic obstructive pulmonary disease with questionnaire, peak flow measurements and spirometry: a cross-sectional study. BMC Res Notes. 2014;7:241. - PMC - PubMed
  24.  
    1. Al Ghobain M, Al-Hajjaj MS, Wali SO. Prevalence of chronic obstructive pulmonary disease among smokers attending primary healthcare clinics in Saudi Arabia. Ann Saudi Med. 2011;31:129–133. - PMC - PubMed
  25.  
    1. Al Ghobain M, Alhamad EH, Alorainy HS, Al Kassimi F, Lababidi H, Al-Hajjaj MS. The prevalence of chronic obstructive pulmonary disease in Riyadh, Saudi Arabia: a BOLD study. Int J Tuberc Lung Dis. 2015;9:1252–1257. - PubMed
  26.  
    1. Al Omari M, Khassawneh BY, Khader Y, Dauod AS, Bergus G. Prevalence of chronic obstructive pulmonary disease among adult male cigarettes smokers: a community-based study in Jordan. Int J Chron Obstruct Pulmon Dis. 2014;9:753–758. - PMC - PubMed
  27.  
    1. Said AF, Ewis AA, Omran AA, Magdy ME, Saleeb MF. Prevalence and predictors of chronic obstructive pulmonary disease among high-risk Egyptians. Egypt J Bronchol. 2015;9:27–33.
  28.  
    1. Badway MS, Hamed AF, Yousef FM. Prevalence of chronic obstructive pulmonary disease (COPD) in Qena Governorate. Egypt J Chest Dis Tuberc. 2016;65:29–34.
  29.  
    1. Waked M, Khayat G, Salameh P. Chronic obstructive pulmonary disease prevalence in Lebanon: a cross-sectional descriptive study. Clin Epidemiol. 2011;3:315–323. - PMC - PubMed
  30.  
    1. Daldoul H, Denguezli M, Jithoo A, et al. Prevalence of COPD and tobacco smoking in Tunisia: results from the BOLD study. Int J Environ Res Public Health. 2013;10:7257–7271. - PMC - PubMed
  31.  
    1. El Rhazi K, Nejjari C, BenJelloun MC, El Biaze M, Attassi M, Garcia-Larsen V. Prevalence of chronic obstructive pulmonary disease in Fez, Morocco: results from the BOLD study. Int J Tuberc Lung Dis. 2016;20:136–141. - PubMed
  32.  
    1. World Health Organization Prevalence of tobacco smoking. [Accessed January 15, 2017]. Available from: http://www.who.int/gho/tobacco/use/en.
  33.  
    1. Jithoo A, Enright PL, Burney P, et al. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease Study. Eur Respir J. 2013;41:548–555. - PMC - PubMed
  34.  
    1. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875–1881. - PubMed
  35.  
    1. Landis SH, Muellerova H, Mannino DM, et al. Continuing to Confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611. - PMC - PubMed
  36.  
    1. Kart L, Akkoyunlu ME, Bayram M, et al. COPD: an underdiagnosed disease at hospital environment. Wien Klin Wochenschr. 2014;126:73–78. - PubMed
  37.  
    1. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:693–718. - PubMed
  38.  
    1. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847–852. - PubMed
  39.  
    1. Khattab A, Javaid A, Iraqi G, et al. Smoking habits in the Middle East and North Africa: results of the BREATHE study. Respir Med. 2012;106(Suppl 2):S16–S24. - PubMed
  40.  
    1. Al Zaabi A, Mahboub BH, Vats MG, Iqbal MN, Vats DM. Chronic obstructive pulmonary disease in Middle East and UAE: an unrecognized underestimated epidemic. J Lung Pulm Respir Res. 2016;3:00089.
  41.  
    1. Maziak W, Ward KD, Soweid RA, Eissenberg T. Tobacco smoking using a waterpipe: a re-emerging strain in a global epidemic. Tob Control. 2004;13:327–333. - PMC - PubMed
  42.  
    1. Akl EA, Gaddam S, Gunukula SK, Honeine R, Jaoude PA, Irani J. The effects of water pipe tobacco smoking on health outcomes: a systematic review. Int J Epidemiol. 2010;39:834–857. - PubMed
  43.  
    1. She J, Yang P, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest. 2014;146:924–931. - PubMed
  44.  
    1. Haddad L, Kelly DL, Weglicki LS, Barnett TE, Ferrell AV, Ghadban R. A systematic review of effects of waterpipe smoking on cardiovascular and respiratory health outcomes. Tob Use Insights. 2016;9:13–28. - PMC - PubMed
  45.  
    1. Salameh P, Waked M, Khoury F, et al. Waterpipe smoking and dependence are associated with chronic bronchitis: a case-control study in Lebanon. East Mediterr Health J. 2012;18:996–1004. - PubMed
  46.  
    1. Mohammad Y, Shaaban R, Al-Zahab BA, Khaltaev N, Bousquet J, Dubaybo B. Impact of active and passive smoking as risk factors for asthma and COPD in women presenting to primary care in Syria: first report by the WHO-GARD survey group. Int J Chron Obstruct Pulmon Dis. 2013;8:473–482. - PMC - PubMed
  47.  
    1. Al-Houqani M, Ali R, Hajat C. Tobacco smoking using medwakh is an emerging health problem: evidence from a large cross-sectional survey in the United Arab Emirates. PLoS One. 2012;7:e39189. - PMC - PubMed
  48.  
    1. Salameh P, Salame J, Khayat G, et al. Exposure to outdoor air pollution and chronic bronchitis in adults: a case-control study. Int J Occup Environ Med. 2012;3:165–177. - PubMed
  49.  
    1. Waked M, Salame J, Khayat G, Salameh P. Correlates of COPD and chronic bronchitis in nonsmokers: data from a cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2012;7:577–585. - PMC - PubMed
  50.  
    1. Denguezli M, Daldoul H, Harrabi I, et al. COPD in nonsmokers: reports from the Tunisian population-based Burden of Obstructive Lung Disease study. PLoS One. 2016;11:e0151981. - PMC - PubMed
  51.  
    1. Gauderman WJ, Avol E, Gilliland F, et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med. 2004;351:1057–1067. - PubMed
  52.  
    1. Gauderman WJ, Vora H, McConnell R, et al. Effect of exposure to traffic on lung development from 10 to 18 years of age: a cohort study. Lancet. 2007;369:571–577. - PubMed
  53.  
    1. Rojas-Martinez R, Perez-Padilla R, Olaiz-Fernandez G, et al. Lung function growth in children with long-term exposure to air pollutants in Mexico City. Am J Respir Crit Care Med. 2007;176:377–384. - PubMed
  54.  
    1. Downs SH, Schindler C, Liu LJ, et al. Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med. 2007;357:2338–2347. - PubMed
  55.  
    1. Euler G, Abbey D, Magie A, Hodgkin J. Chronic obstructive pulmonary disease symptom effects of long-term cumulative exposure to ambient levels of total suspended particulates and sulfur dioxide in California Seventh-Day Adventist residents. Arch Environ Health. 1987;42:213–222. - PubMed
  56.  
    1. Abbey D, Burchette R, Knutsen S, McDonnel W, Lebowitz M, Enright P. Long-term particulate and other pollutants and lung function in nonsmokers. Am J Respir Crit Care Med. 1998;158:289–298. - PubMed
  57.  
    1. Schikowski T, Sugiri D, Ranft U, et al. Long-term air pollution exposure and living close to busy roads are associated with COPD in women. Respir Res. 2005;6:152. - PMC - PubMed
  58.  
    1. Andersen ZJ, Hvidberg M, Jensen SS, et al. COPD and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med. 2011;183:455–461. - PubMed
  59.  
    1. Smith KR. Biofuels, Air Pollution, and Health. New York: Plenum Press; 1987.
  60.  
    1. Pandey M, Basnyat B, Neupane R. Chronic bronchitis and cor pulmonale in Nepal. Lung India. 1988;6:209–210.
  61.  
    1. Albalak R, Frisancho AR, Keeler GJ. Domestic biomass fuel combustion and chronic bronchitis in two rural Bolivian villages. Thorax. 1999;54:1004–1008. - PMC - PubMed
  62.  
    1. Behera D. An analysis of effect of common domestic fuels on respiratory function. Indian J Chest Dis Allied Sci. 1997;39:235–243. - PubMed
  63.  
    1. Behera D, Jindal SK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest. 1991;100:385–388. - PubMed
  64.  
    1. Behera D, Jindal SK, Malhotra HS. Ventilatory function in nonsmoking rural Indian women using different cooking fuels. Respiration. 1994;61:89–92. - PubMed
  65.  
    1. Cetinkaya F, Gülmez I, Aydin T, Oztürk Y, Ozesmi M, Demir R. Prevalence of chronic bronchitis and associated risk factors in a rural area of Kayseri, central Anatolia, Turkey. Monaldi Arch Chest Dis. 2000;55:189–193. - PubMed
  66.  
    1. Dossing M, Khan J, al-Rabiah F. Risk factors for chronic obstructive lung disease in Saudi Arabia. Respir Med. 1994;88:519–522. - PubMed
  67.  
    1. Ekici A, Ekici M, Kurtipek E, et al. Obstructive airway diseases in women exposed to biomass smoke. Environ Res. 2005;99:93–98. - PubMed
  68.  
    1. Kiraz K, Kart L, Demir R, et al. Chronic pulmonary disease in rural women exposed to biomass fumes. Clin Invest Med. 2003;26:243–248. - PubMed
  69.  
    1. Pandey MR. Domestic smoke pollution and chronic bronchitis in a rural community of the hill region of Nepal. Thorax. 1984;39:337–339. - PMC - PubMed
  70.  
    1. Pérez-Padilla R, Regalado J, Vedal S, et al. Exposure to biomass smoke and chronic airway disease in Mexican women: a case-control study. Am J Respir Crit Care Med. 1996;154:701–706. - PubMed
  71.  
    1. Regalado J, Pérez-Padilla R, Sansores R, et al. The effect of biomass burning on respiratory symptoms and lung function in rural Mexican women. Am J Respir Crit Care Med. 2006;174:901–905. - PubMed
  72.  
    1. Shrestha IL, Shrestha SL. Indoor air pollution from biomass fuels and respiratory health of the exposed population in Nepalese households. Int J Occup Environ Health. 2005;11:150–160. - PubMed
  73.  
    1. Menezes AM, Victora CG, Rigatto M. Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study. Thorax. 1994;49:1217–1221. - PMC - PubMed
  74.  
    1. Dutt D, Srinivasa DK, Rotti SB, Sahai A, Konar D. Effect of indoor air pollution on the respiratory system of women using different fuels for cooking in an urban slum of Pondicherry. Natl Med J India. 1996;9:113–117. - PubMed
  75.  
    1. Ellegard A. Cooking fuel smoke and respiratory symptoms among women in low-income areas in Maputo. Environ Health Perspect. 1996;104:980–985. - PMC - PubMed
  76.  
    1. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural south China. Thorax. 2007;62:889–897. - PMC - PubMed
  77.  
    1. Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for obstructive airways disease among women. Chest. 1996;109:115–119. - PubMed
  78.  
    1. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramirez-Sarmiento A, Anto JM, Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:542–546. - PubMed
  79.  
    1. Caballero A, Torres-Duque CA, Jaramillo C, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study) Chest. 2008;133:343–349. - PubMed
  80.  
    1. Aljarallah B, Ali A, Dowaidar M, Settin A. Prevalence of α-1-antitrypsin gene mutations in Saudi Arabia. Saudi J Gastroenterol. 2011;17:256–260. - PMC - PubMed
  81.  
    1. Brown PJ, Greville HW, Finucane KE. Asthma and irreversible airflow obstruction. Thorax. 1984;39:131–136. - PMC - PubMed
  82.  
    1. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J. 1999;14:892–896. - PubMed
  83.  
    1. Cassino C, Berger KI, Goldring RM, et al. Duration of asthma and physiologic outcomes in elderly nonsmokers. Am J Respir Crit Care Med. 2000;162:1423–1428. - PubMed
  84.  
    1. Connolly CK, Chan NS, Prescott RJ. The relationship between age and duration of asthma and the presence of persistent obstruction in asthma. Postgrad Med J. 1988;64:422–425. - PMC - PubMed
  85.  
    1. Beaglehole R, Bonita R, Alleyne G, et al. UN High-Level Meeting on Non-Communicable Diseases: addressing four questions. Lancet. 2011;378:449–455. - PubMed
  86.  
    1. European COPD Coalition Prevalence in EU. [Accessed January 14, 2017]. Available from: http://www.copdcoalition.eu/about-copd/prevalence.
  87.  
    1. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:188–207. - PubMed
  88.  
    1. Centers for Disease Control and Prevention Chronic obstructive pulmonary disease among adults: United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:938–943. - PubMed
  89.  
    1. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD. 2006;3:211–218. - PubMed
  90.  
    1. Mehrotra A, Oluwole AM, Gordon SB. The burden of COPD in Africa: a literature review and prospective survey of the availability of spirometry for COPD diagnosis in Africa. Trop Med Int Health. 2009;14:840–848. - PubMed
  91.  
    1. Shaya FT, El Khoury AC, Samant ND, Scharf SM. Utilization of health care resources in a high-risk Medicaid population with chronic obstructive pulmonary disease. Phys Ther. 2006;31:261–268.
  92.  
    1. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med. 2008;102:124856. - PubMed
  93.  
    1. Chung F, Barnes N, Allen M, et al. Assessing the burden of respiratory disease in the UK. Respir Med. 2002;96:963–975. - PubMed
  94.  
    1. Mannino DM, Bradman S. The epidemiology and economics of chronic pulmonary obstructive disease. Proc Am Thorac Soc. 2007;4:502–506. - PubMed
  95.  
    1. Wouters EF. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S51–S59. - PubMed
  96.  
    1. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med. 2003;97(Suppl C):S3–S14. - PubMed
  97.  
    1. Simon-Tuval T, Scharf SM, Maimon N, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Determinants of elevated healthcare utilization in patients with COPD. Respir Res. 2011;12:7. - PMC - PubMed
  98.  
    1. Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Res. 2011;105:1516–1522. - PubMed
  99.  
    1. Alzaabi A, Mahboub B, Salhi H, Kajingu W, Rashid N, El-Hasnaoui A. Waterpipe use in the Middle East and North Africa: data from the Breathe study. Nicotine Tob Res. 2016 Oct 10; Epub. - PubMed
  100.  
    1. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–272. - PubMed
  101.  
    1. de los Monteros MJ, Peña C, Hurtado EJ, Jareño J, Miravitlles M. Variability of respiratory symptoms in severe COPD. Arch Bronconeumol. 2012;48:3–7. - PubMed
  102.  
    1. Zwar NA, Marks GB, Hermiz O, et al. Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice. Med J Aust. 2011;195:168–171. - PubMed
  103.  
    1. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teght-soonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990;142:1009–1014. - PubMed
  104.  
    1. Burrows B, Niden AH, Barclay WR, et al. Chronic obstructive lung disease – II: relationship of clinical and physiologic findings to the severity of airways obstruction. Am Rev Respir Dis. 1965;91:665–678. - PubMed
  105.  
    1. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet. 1965;1:775–779. No authors listed. - PubMed
  106.  
    1. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151–1156. - PubMed
  107.  
    1. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791–1797. - PubMed
  108.  
    1. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005–2011. - PubMed
  109.  
    1. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest. 1993;104:254–258. - PubMed
  110.  
    1. Loveridge B, West P, Kryger MH, Anthonisen NR. Alteration in breathing pattern with progression of chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;134:930–934. - PubMed
  111.  
    1. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968. - PubMed
  112.  
    1. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586. - PMC - PubMed
  113.  
    1. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434–1440. - PubMed
  114.  
    1. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56:880–887. - PMC - PubMed
  115.  
    1. Jones P, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD assessment test (CATTM) scores. BMC Pul Med. 2011;11:42. - PMC - PubMed
  116.  
    1. Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013;42:647–654. - PubMed
  117.  
    1. Jones PW. COPD assessment test: rationale, development, validation and performance. COPD. 2013;10:269–271. - PubMed
  118.  
    1. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes. 2003;1:13. - PMC - PubMed
  119.  
    1. Reda AA, Kotz D, Kocks JW, Wesseling G, van Schayck CP. Reliability and validity of the clinical COPD questionnaire and chronic respiratory questionnaire. Respir Med. 2010;104:1675–1682. - PubMed
  120.  
    1. Miller MR, Hankinson J, Brusasco V, et al. Standardization of spirom-etry. Eur Respir J. 2005;26:319–338. - PubMed
  121.  
    1. Buist AS, Mcburnie MA, Vollmer WM, et al. International variations in the prevalence of COPD (the BOLD study): a population based prevalence study. Lancet. 2007;370:741–750. - PubMed
  122.  
    1. Hurst JR, Wedzicha JA. What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines. Thorax. 2007;62:198–199. - PMC - PubMed
  123.  
    1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. - PubMed
  124.  
    1. Soler-Cataluña JJ, Martínez-García MA, Sánchez PR, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. - PMC - PubMed
  125.  
    1. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–2107. - PubMed
  126.  
    1. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. Am Rev Respir Dis. 1990;141:613–617. - PubMed
  127.  
    1. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. Ann Intern Med. 1986;105:503–507. - PubMed
  128.  
    1. Burgel PR, Roche N, Paillasseur JL, et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J. 2012;40:495–496. - PubMed
  129.  
    1. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol. 2012;48:247–257. - PubMed
  130.  
    1. Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) phenotypes. Thorax. 2011;66:430–437. - PubMed
  131.  
    1. Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome (ACOS)? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48:664–673. - PubMed
  132.  
    1. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016;71:118–125. - PMC - PubMed
  133.  
    1. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials. Lancet Respir Med. 2015;3:435–442. - PubMed
  134.  
    1. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44:789–791. - PubMed
  135.  
    1. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–2073. - PubMed
  136.  
    1. Kelly AM, McAlpine R, Kyle E. How accurate are pulse oximeters in patients with acute exacerbations of chronic obstructive airways disease? Respir Med. 2001;95:336–340. - PubMed
  137.  
    1. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23:28–33. - PubMed
  138.  
    1. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003;167:544–549. - PubMed
  139.  
    1. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56:880–887. - PMC - PubMed
  140.  
    1. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–1012. - PubMed
  141.  
    1. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554. - PubMed
  142.  
    1. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503–513. - PMC - PubMed
  143.  
    1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed
  144.  
    1. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1:524–533. - PubMed
  145.  
    1. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–1103. - PubMed
  146.  
    1. Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79:695–708. - PMC - PubMed
  147.  
    1. Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT) Respir Res. 2015;16:92. - PMC - PubMed
  148.  
    1. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199–209. - PubMed
  149.  
    1. Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153–1162. - PubMed
  150.  
    1. Singh D, Corradi M, Spinola M, Petruzzelli S, Papi A. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med. 2016;26:16030. - PMC - PubMed
  151.  
    1. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66:699–708. - PubMed
  152.  
    1. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116:652–657. - PubMed
  153.  
    1. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001–1006. - PubMed
  154.  
    1. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68:1105–1113. - PubMed
  155.  
    1. Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12:27–34. - PubMed
  156.  
    1. Festic E, Scanlon PD. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease: a double effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2015;191:141–148. - PMC - PubMed
  157.  
    1. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glyco-pyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. - PubMed
  158.  
    1. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741–750. - PubMed
  159.  
    1. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–973. - PubMed
  160.  
    1. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–866. - PubMed
  161.  
    1. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189:1503–1508. - PMC - PubMed
  162.  
    1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. - PubMed
  163.  
    1. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a bio-marker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:523–525. - PMC - PubMed
  164.  
    1. Pascoe S, Locantore N, Dransfield M, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–442. - PubMed
  165.  
    1. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Resp Crit Care Med. 2013;188:e13–e64. - PubMed
  166.  
    1. Garvey C, Bayles MP, Hamm LF, et al. Pulmonary rehabilitation exercise prescription in chronic obstructive pulmonary disease: review of selected guidelines. J Cardiopulm Rehabil Prev. 2016;6:75–83. - PubMed
  167.  
    1. Ries AL, Make BJ, Lee SM, et al. The effects of pulmonary rehabilitation in the National Emphysema Treatment Trial. Chest. 2005;128:3799–3809. - PubMed
  168.  
    1. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–191. - PubMed
  169.  
    1. Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality: a systematic review. Respir Res. 2005 Jun 8;6:54. - PMC - PubMed
  170.  
    1. Ortega F, Toal J, Cejudo P, et al. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2002;166:669–674. - PubMed
  171.  
    1. Garber CE, Blissmer B, Deschenes MR, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuro-motor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43:1334–1359. - PubMed
  172.  
    1. Horowitz MB, Littenberg B, Mahler DA. Dyspnea ratings for prescribing exercise intensity in patients with COPD. Chest. 1996;109:1169–1175. - PubMed
  173.  
    1. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am J Respir Crit Care Med. 2000;161:381–390. - PubMed
  174.  
    1. Pelkonen M, Tukiainen H, Tervahauta M, et al. Pulmonary function, smoking cessation and 30-year mortality in middle aged Finnish men. Thorax. 2000;55:746–750. - PMC - PubMed
  175.  
    1. Carmody TP, Duncan C, Simon JA, et al. Hypnosis for smoking cessation: a randomized trial. Nicotine Tob Res. 2008;10:811–818. - PubMed
  176.  
    1. Odum LE, O’Dell KA, Schepers JS. Electronic cigarettes: do they have a role in smoking cessation? J Pharm Pract. 2012;25:611–614. - PubMed
  177.  
    1. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practice (ACIP) MMWR Morb Mortal Wkly Rep. 2014;63:822–825. - PMC - PubMed
  178.  
    1. Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable COPD. Cochrane Database Syst Rev. 2012;12:CD000998. - PubMed
  179.  
    1. Struik FM, Lacasse Y, Goldstein R, Kerstjens HM, Wijkstra PJ. Nocturnal non-invasive positive pressure for stable COPD. Cochrane Database Syst Rev. 2013:CD002878. - PMC - PubMed
  180.  
    1. Tiong LU, Davies R, Gibson PG, et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev. 2006:CD001001. - PubMed
  181.  
    1. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates – 2014: an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15. - PubMed
  182.  
    1. International Society for Heart and Lung Transplantation Overall lung transplantation statistics. 2016. [Accessed July 19, 2017]. Available from: https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry.

Page Navigation